This inventor holds 1 USPTO granted patent. Top assignee: E. R. Squibb Sons, Inc.. Active years: 1991.
Company Filing History:
Years Active: 1991
Title: **Alan F. Feldman: Innovator in Pharmaceutical Processes**
Introduction
Alan F. Feldman is a notable inventor based in Philadelphia, PA. He has contributed significantly to the field of pharmaceuticals, particularly through his innovative processes for drug isolation. With one patent to his name, Alan has made strides in improving the efficiency and safety of pharmaceutical manufacturing.
Latest Patents
Alan F. Feldman's patent, titled "Process for Direct Isolation of Captopril," presents a groundbreaking methodology for isolating captopril from a specific substrate. The process involves the treatment of the substrate with an aqueous alkali metal hydroxide, ensuring a high concentration of 4M or greater. This innovative approach eliminates the need for organic solvents and zinc treatments typically required to manage impurities, allowing for the direct crystallization of captopril from an aqueous solution. This advancement not only enhances the purity of the final product but also streamlines the isolation process in pharmaceutical manufacturing.
Career Highlights
Feldman is associated with E.R. Squibb & Sons, Inc., a company known for its commitment to pharmaceutical research and development. His work has helped push the boundaries of traditional methods, showcasing his dedication to innovation in the industry. Through his patent, Alan has provided the pharmaceutical sector with an alternative to conventional practices, promoting both efficiency and environmental sustainability.
Collaborations
Throughout his career, Alan has collaborated with esteemed colleagues, including Neal G. Anderson and David A. Lust. These partnerships highlight the importance of teamwork in scientific advancement, as they share a commitment to developing effective pharmaceutical solutions.
Conclusion
Alan F. Feldman's contributions to the field of pharmaceuticals illustrate the impact of innovative processes on drug manufacturing. His patented methodology for isolating captopril represents a significant step forward in improving pharmaceutical production. As he continues to work with E.R. Squibb & Sons, Inc. and collaborate with fellow inventors, the future of pharmaceutical innovation remains bright.